Overview

A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis

Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to assess the tolerability and efficacy of a 0.10% or 0.05% PTH (1-34) parathyroid hormone peptide gel in the treatment of mild to moderate plaque psoriasis in comparison to treatment with the placebo gel alone.
Phase:
Phase 2
Details
Lead Sponsor:
Manhattan Pharmaceuticals
Collaborator:
Therapeutics, Inc.
Treatments:
Parathyroid Hormone